View in EDS HTML Full Text PDF Full Text

Anlotinib as a third-line or further treatment for recurrent or metastatic nasopharyngeal carcinoma: a single-arm, phase 2 clinical trial.

Saved in:
Bibliographic Details
Title: Anlotinib as a third-line or further treatment for recurrent or metastatic nasopharyngeal carcinoma: a single-arm, phase 2 clinical trial.
Authors: Fang, Yu1,2,3 (AUTHOR), Su, Ning1,2,4 (AUTHOR), Zou, Qihua1,2 (AUTHOR), Cao, Yi1,2 (AUTHOR), Xia, Yi1,2 (AUTHOR), Tang, Linquan2,5 (AUTHOR), Tian, Xiaopeng1,2 (AUTHOR), Liu, Panpan1,2 (AUTHOR), Cai, Qingqing1,2 (AUTHOR) caiqq@sysucc.org.cn
Source: BMC Medicine. 11/7/2023, Vol. 21 Issue 1, p1-10. 10p.
Database: Academic Search Ultimate
Full text is not displayed to guests.
Description
ISSN:17417015
DOI:10.1186/s12916-023-03140-x